Though many patients will likely continue to use interferon beta drugs as a way to control relapses, this new study may significantly change how MS is treated.  From a broader perspective, this development may also ultimately change the process for testing and evaluating drugs because the experience with interferon beta provides a striking example of how a tremendous amount of money can be spent on drugs that were not effective in doing what patients thought they were doing—in this case slowing the progression of MS.   

 More at   http://www.healthcentral.com/multiple-sclerosis/c/215658/154812/found/2